Emerging Markers of Atherosclerosis Before and After Bariatric Surgery

Obesity Surgery

Volumn 25, Issue 3, 2015, Pages 486-493

  Domienik Karłowicz, Justyna ^a   Rymarczyk, Zuzanna ^a   Dzikowska Diduch, Olga ^a   Lisik, Wojciech ^a   Chmura, Andrzej ^a   Demkow, Urszula ^a   Pruszczyk, Piotr ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Atheroslerosis; Bariatric sugery; Emerging markers; MMP; Morbid obesity

Indexed keywords

ADIPONECTIN; BIOCHEMICAL MARKER; CD40 LIGAND; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ADIPOQ PROTEIN, HUMAN; BIOLOGICAL MARKER; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; ATHEROSCLEROSIS; BARIATRIC SURGERY; BODY FAT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; ENZYME BLOOD LEVEL; FAT MASS; FEMALE; HUMAN; HYPERTENSION; HYPOADIPONECTINEMIA; IMPAIRED GLUCOSE TOLERANCE; LABORATORY TEST; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SLEEP DISORDERED BREATHING; BLOOD; BODY MASS; CASE CONTROL STUDY; COMPLICATION; DEFICIENCY; FOLLOW UP; INBORN ERROR OF METABOLISM; MIDDLE AGED; OBESITY, MORBID; PHYSIOLOGY; WEIGHT REDUCTION;

ADIPONECTIN; ADULT; ATHEROSCLEROSIS; BARIATRIC SURGERY; BIOMARKERS; BODY MASS INDEX; CASE-CONTROL STUDIES; CD40 LIGAND; E-SELECTIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MATRIX METALLOPROTEINASES; METABOLISM, INBORN ERRORS; MIDDLE AGED; OBESITY, MORBID; PLASMINOGEN ACTIVATOR INHIBITOR 1; WEIGHT LOSS;

EID: 84925507706     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-014-1407-7     Document Type: Article

References (41)

1. Havel PJ. Update on adipocyte hormones. Diabetes. 2004;53 Suppl 1:S143–51. doi:10.2337/diabetes.53.2007.S143.
2. McGrath JC, Deighan C, Briones AM, et al. New aspects of vascular remodelling: the involvement of all vascular cell types. Exp Physiol. 2005;90(4):469–75. doi:10.1113/expphysiol.2005.030130. Epub 2005/05/17.
3. Vinay Kumar RSC, Stanley L. Robbins. Patologia. 2005.
4. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis. Circ Res. 2002;90(3):251–62.
5. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94(6):2493–503.
6. Bouloumie A, Sengenes C, Portolan G, et al. Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes. 2001;50(9):2080–6.
7. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res. 2006;69(3):614–24.
8. Newby AC. Do metalloproteinases destabilize vulnerable atherosclerotic plaques? Curr Opin Lipidol. 2006;17(5):556–61.
9. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103(8):1057–63.
10. Ryan AS, Berman DM, Nicklas BJ, et al. Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care. 2003;26(8):2383–8.
11. Owecki M, Miczke A, Pupek-Musialik D, et al. Circulating serum adiponectin concentrations do not differ between obese and non-obese caucasians and are unrelated to insulin sensitivity. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2007;39(1):25–30.
12. Ryan AS, Nicklas BJ, Berman DM, et al. Adiponectin levels do not change with moderate dietary induced weight loss and exercise in obese postmenopausal women. Int J Obes Relat Metab Disord: J Int Assoc Study Obes. 2003;27(9):1066–71.
13. Abbasi F, Lamendola C, McLaughlin T, et al. Plasma adiponectin concentrations do not increase in association with moderate weight loss in insulin-resistant, obese women. Metab Clin Exp. 2004;53(3):280–3.
14. Owecki M. Rozprawa habilitacyjna. Analiza stężeń adiponektyny w surowicy i ocena ich związku z wybranymi parametrami metabolizmu oraz badanie polimorfizmu genu adiponektyny w otyłości u ludzi: Katedra i Klinika Endokrynologii, Przemiany Materii i Chorób Wewnętrznych Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu; 2008.
15. Schondorf T, Maiworm A, Emmison N, et al. Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk. Clin Lab. 2005;51(9–10):489–94. Epub 2005/11/16.
16. Trujillo ME, Scherer PE. Adiponectin–journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257(2):167–75. doi:10.1111/j.1365-2796.2004.01426.x. Epub 2005/01/20.
17. Unek IT, Bayraktar F, Solmaz D, et al. Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome. Metabolism. 2010;59(3):305–13. doi:10.1016/j.metabol.2009.04.034. Epub 2009/12/17.
18. Huang Y, Qiu J, Zhang D, et al. Elevated soluble CD40 ligand in diabetic patients with painless myocardial infarction. Biofactors. 2011;37(2):88–94. doi:10.1002/biof.145. Epub 2011/04/14.
19. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation. 2004;109(21):2524–8. doi:10.1161/01.CIR.0000129773.70647.94. Epub 2004/05/12.
20. Palomo IG, Jaramillo JC, Alarcon ML, et al. Increased concentrations of soluble vascular cell adhesion molecule-1 and soluble CD40L in subjects with metabolic syndrome. Mol Med Report. 2009;2(3):481–5. doi:10.3892/mmr_00000125. Epub 2009/05/01.
21. Unek IT, Bayraktar F, Solmaz D, et al. The levels of soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese people. Clin Med Res. 2010;8(2):89–95. doi:10.3121/cmr.2010.889. Epub 2010/07/28.
22. Guldiken S, Demir M, Arikan E, et al. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res. 2007;119(1):79–84. doi:10.1016/j.thromres.2005.12.019. Epub 2006/02/16.
23. Hanusch-Enserer U, Zorn G, Wojta J, et al. Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur Heart J. 2009;30(12):1516–24. doi:10.1093/eurheartj/ehp108. Epub 2009/04/22.
24. Primrose JN, Davies JA, Prentice CR, et al. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost. 1992;68(4):396–9. Epub 1992/10/05.
25. Diabetologiczne PT. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2011. Diabetologia Praktyczna. 2011;12, Suplement A.
26. Fried M, Hainer V, Basdevant A, et al. Interdisciplinary European guidelines for surgery for severe (morbid) obesity. Obes Surg. 2007;17(2):260–70. Epub 2007/05/05.
27. Derosa G, Ferrari I, D’Angelo A, et al. Matrix metalloproteinase-2 and −9 levels in obese patients. Endothelium: J Endothelial Cell Res. 2008;15(4):219–24.
28. Cicero AF, Derosa G, Manca M, et al. Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. Endothelium: Journal Endothelial Cell Res. 2007;14(4–5):193–8.
29. Woelnerhanssen B, Peterli R, Steinert RE, Peters T, Borbely Y, Beglinger C. Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy-a prospective randomized trial. Surgery for obesity and related diseases: official journal of the American Society for Bariatric Surgery. 2011(Journal Article).
30. Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17(9):961–9. Epub 1994/09/01.
31. Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122(7):481–6. Epub 1995/04/01.
32. Promintzer-Schifferl M, Prager G, Anderwald C, et al. Effects of gastric bypass surgery on insulin resistance and insulin secretion in nondiabetic obese patients. Obesity (Silver Spring). 2011;19(7):1420–6. doi:10.1038/oby.2011.92. Epub 2011/04/16.
33. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107(5):671–4. Epub 2003/02/13.
34. Kosmala W, Plaksej R, Przewlocka-Kosmala M, Kuliczkowska-Plaksej J, Bednarek-Tupikowska G, Mazurek W. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function. International journal of obesity (2005). 2008;32(5):763–71.
35. Unal R, Yao-Borengasser A, Varma V, et al. Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone. J Clin Endocrinol Metab. 2010;95(6):2993–3001.
36. Catalan V, Gomez-Ambrosi J, Rodriguez A, et al. Increased adipose tissue expression of lipocalin-2 in obesity is related to inflammation and matrix metalloproteinase-2 and metalloproteinase-9 activities in humans. J Mol Med (Berlin, Germany). 2009;87(8):803–13.
37. Hanusch-Enserer U, Zorn G, Wojta J, et al. Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur Heart J. 2009;30(12):1516–24.
38. Laimer M, Kaser S, Kranebitter M, et al. Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int J Obes. 2005;29(5):498–501.
39. Sheu WH, Chang TM, Lee WJ, et al. Effect of weight loss on proinflammatory state of mononuclear cells in obese women. Obesity (Silver Spring). 2008;16(5):1033–8.
40. Madsen EL, Bruun JM, Skogstrand K, et al. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects. Metab Clin Exp. 2009;58(7):946–53.
41. Schernthaner GH, Kopp HP, Krzyzanowska K, et al. Soluble CD40L in patients with morbid obesity: significant reduction after bariatric surgery. Eur J Clin Invest. 2006;36(6):395–401. doi:10.1111/j.1365-2362.2006.01649.x. Epub 2006/05/11.